Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2021 Feb 8

PMID 33553916

Citations 21

Authors

Martina di Francesco

Christian Celia

Maria Chiara Cristiano

Nicola dAvanzo

Barbara Ruozi

Constantin Mircioiu

Donato Cosco

Luisa Di Marzio

Massimo Fresta

Affiliations

Soon will be listed here.

Abstract

Doxorubicin hydrochloride (DOX) is currently used to treat orthotropic and metastatic breast cancer. Because of its side effects, the use of DOX in cancer patients is sometimes limited; for this reason, several scientists tried designing drug delivery systems which can improve drug therapeutic efficacy and decrease its side effects. In this study, we designed, prepared, and physiochemically characterized nonionic surfactant vesicles (NSVs) which are obtained by self-assembling different combinations of hydrophilic (Tween 20) and hydrophobic (Span 20) surfactants, with cholesterol. DOX was loaded in NSVs using a passive and pH gradient remote loading procedure, which increased drug loading from ∼1 to ∼45%. NSVs were analyzed in terms of size, shape, size distribution, zeta potential, long-term stability, entrapment efficiency, and release kinetics, and nanocarriers having the best physiochemical parameters were selected for further tests. NSVs with and without DOX were stable and showed a sustained drug release up to 72 h. studies, with MCF-7 and MDA MB 468 cells, demonstrated that NSVs, containing Span 20, were better internalized in MCF-7 and MDA MB 468 cells than NSVs with Tween 20. NSVs increased the anticancer effect of DOX in MCF-7 and MDA MB 468 cells, and this effect is time and dose dependent. studies using metastatic and nonmetastatic breast cancer cells also demonstrated that NSVs, containing Span 20, had higher cytotoxicity than NSVs with Tween 20. The resulting data suggested that DOX-loaded NSVs could be a promising nanocarrier for the potential treatment of metastatic breast cancer.

Citing Articles

Current Paradigms and Future Challenges in Harnessing Nanocellulose for Advanced Applications in Tissue Engineering: A Critical State-of-the-Art Review for Biomedicine.

Dar M, Xie R, Liu J, Ali S, Pawar K, Sudiana I Int J Mol Sci. 2025; 26(4).

PMID: 40003914 PMC: 11855852. DOI: 10.3390/ijms26041449.

The effects of exercise and mitochondrial transplantation alone or in combination against Doxorubicin-induced skeletal muscle atrophy.

Kubat G, Ulger O, Atalay O, Fatsa T, Turkel I, Ozerklig B J Muscle Res Cell Motil. 2024; 45(4):233-251.

PMID: 38822935 DOI: 10.1007/s10974-024-09676-6.

Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells.

Saharkhiz S, Nasri N, Naderi N, Dini G, Ghalehshahi S, Firoozbakht F Int J Pharm X. 2024; 7:100237.

PMID: 38516198 PMC: 10955288. DOI: 10.1016/j.ijpx.2024.100237.

Design, Synthesis, and Anti-Breast Cancer Potential of Imidazole-Pyridine Hybrid Molecules and Ehrlich Ascites Carcinoma Growth Inhibitory Activity Assessment .

Aruchamy B, Kuruburu M, Bovilla V, Madhunapantula S, Drago C, Benny S ACS Omega. 2023; 8(43):40287-40298.

PMID: 37929115 PMC: 10620790. DOI: 10.1021/acsomega.3c04384.

Perspective use of bio-adhesive liquid crystals as ophthalmic drug delivery systems.

Tarsitano M, Mancuso A, Cristiano M, Urbanek K, Torella D, Paolino D Sci Rep. 2023; 13(1):16188.

PMID: 37758768 PMC: 10533901. DOI: 10.1038/s41598-023-42185-z.

References

Rinaldi F, Del Favero E, Moeller J, Hanieh P, Passeri D, Rossi M . Hydrophilic Silver Nanoparticles Loaded into Niosomes: Physical-Chemical Characterization in View of Biological Applications. Nanomaterials (Basel). 2019; 9(8). PMC: 6724070. DOI: 10.3390/nano9081177. View

Mayer L, Tai L, Ko D, Masin D, GINSBERG R, Cullis P . Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49(21):5922-30. View

Papadopoulou V, Kosmidis K, Vlachou M, Macheras P . On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 2005; 309(1-2):44-50. DOI: 10.1016/j.ijpharm.2005.10.044. View

Palchetti S, Colapicchioni V, Digiacomo L, Caracciolo G, Pozzi D, Capriotti A . The protein corona of circulating PEGylated liposomes. Biochim Biophys Acta. 2015; 1858(2):189-96. DOI: 10.1016/j.bbamem.2015.11.012. View

Hafner A, Lovric J, Lakos G, Pepic I . Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014; 9:1005-23. PMC: 3933707. DOI: 10.2147/IJN.S55359. View

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

Gandhi R, Khatri N, Baradia D, Vhora I, Misra A . Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. Drug Deliv. 2015; 23(4):1152-62. DOI: 10.3109/10717544.2014.999960. View

Pramanik D, Campbell N, Das S, Gupta S, Chenna V, Bisht S . A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget. 2012; 3(6):640-50. PMC: 3442295. DOI: 10.18632/oncotarget.543. View

Wen S, Su S, Liou B, Lin C, Lee K . Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells. Cancer Cell Int. 2018; 18:128. PMC: 6123926. DOI: 10.1186/s12935-018-0625-9. View

10.

Hioki A, Wakasugi A, Kawano K, Hattori Y, Maitani Y . Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature. Biol Pharm Bull. 2010; 33(9):1466-70. DOI: 10.1248/bpb.33.1466. View

11.

Frohlich E . The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012; 7:5577-91. PMC: 3493258. DOI: 10.2147/IJN.S36111. View

12.

Marianecci C, Rinaldi F, Di Marzio L, Mastriota M, Pieretti S, Celia C . Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models. Int J Nanomedicine. 2014; 9:635-51. PMC: 3908944. DOI: 10.2147/IJN.S55066. View

13.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View

14.

Fang Y, Xue J, Gao S, Lu A, Yang D, Jiang H . Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery. Drug Deliv. 2017; 24(sup1):22-32. PMC: 8812578. DOI: 10.1080/10717544.2017.1388451. View

15.

Agarwal R, Katare O, Vyas S . Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001; 228(1-2):43-52. DOI: 10.1016/s0378-5173(01)00810-9. View

16.

Mullis A, Broderick S, Binnebose A, Peroutka-Bigus N, Bellaire B, Rajan K . Data Analytics Approach for Rational Design of Nanomedicines with Programmable Drug Release. Mol Pharm. 2019; 16(5):1917-1928. DOI: 10.1021/acs.molpharmaceut.8b01272. View

17.

Cristiano M, Froiio F, Spaccapelo R, Mancuso A, Nistico S, Udongo B . Sulforaphane-Loaded Ultradeformable Vesicles as A Potential Natural Nanomedicine for the Treatment of Skin Cancer Diseases. Pharmaceutics. 2019; 12(1). PMC: 7023209. DOI: 10.3390/pharmaceutics12010006. View

18.

Pozzi D, Caracciolo G, Digiacomo L, Colapicchioni V, Palchetti S, Capriotti A . The biomolecular corona of nanoparticles in circulating biological media. Nanoscale. 2015; 7(33):13958-66. DOI: 10.1039/c5nr03701h. View

19.

Aggarwal P, Hall J, McLeland C, Dobrovolskaia M, McNeil S . Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009; 61(6):428-37. PMC: 3683962. DOI: 10.1016/j.addr.2009.03.009. View

20.

Primavera R, Palumbo P, Celia C, Cinque B, Carata E, Carafa M . An insight of in vitro transport of PEGylated non-ionic surfactant vesicles (NSVs) across the intestinal polarized enterocyte monolayers. Eur J Pharm Biopharm. 2018; 127:432-442. DOI: 10.1016/j.ejpb.2018.03.013. View